Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model

BACKGROUND: Patients with stable coronary artery disease (CAD) constitute a heterogeneous group in which the treatment benefits by angiotensin‐converting enzyme (ACE)‐inhibitor therapy vary between individuals. Our objective was to integrate clinical and pharmacogenetic determinants in an ultimate c...

Descripción completa

Detalles Bibliográficos
Autores principales: Oemrawsingh, Rohit M., Akkerhuis, K. Martijn, Van Vark, Laura C., Redekop, W. Ken, Rudez, Goran, Remme, Willem J., Bertrand, Michel E., Fox, Kim M., Ferrari, Roberto, Danser, A.H. Jan, de Maat, Moniek, Simoons, Maarten L., Brugts, Jasper J., Boersma, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943245/
https://www.ncbi.nlm.nih.gov/pubmed/27021566
http://dx.doi.org/10.1161/JAHA.115.002688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943245/
https://www.ncbi.nlm.nih.gov/pubmed/27021566
http://dx.doi.org/10.1161/JAHA.115.002688

Ejemplares similares